Pacira Pharmaceuticals buy Royal Bank of Canada
Start price
03.11.23
/
50%
€28.40
Target price
03.11.24
€54.04
Performance (%)
-36.97%
Price
24.07.24
€18.40
Summary
This prediction is currently active. Massive losses of -36.97% have been the result for the BUY prediction by Royal_Bank_of_Canada. This prediction currently runs until 03.11.24. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | -3.158% | -3.158% |
iShares Core DAX® | 0.039% | 0.567% |
iShares Nasdaq 100 | -4.018% | -5.554% |
iShares Nikkei 225® | -2.389% | -1.434% |
iShares S&P 500 | -2.115% | -2.351% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $67.00 to $58.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.20
01.03.24
01.03.24
€41.56
01.03.25
01.03.25
-30.53%
24.07.24
24.07.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€27.40
03.10.23
03.10.23
€65.04
03.10.24
03.10.24
-33.58%
24.07.24
24.07.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€34.80
03.08.23
03.08.23
€62.07
03.08.24
03.08.24
-47.13%
24.07.24
24.07.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€40.00
01.03.23
01.03.23
€71.20
01.03.24
01.03.24
-34.50%
02.03.24
02.03.24